Option chain shows key data for Guardian Pharmacy Service's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Guardian Pharmacy Service.

Guardian Pharmacy Service (NYSE:GRDN) Stock, Option Chain

Guardian Pharmacy Service

Guardian Pharmacy Services Inc is a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs, and .BHFs.

AECOM

News

Pre-Market Outlook

Markets

Movers

FFIC

GRDN

GRFS

GSAT

HAFC

INCY

NEXN

Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

pharmaceutical ai-generated

Analyst Color

Equities

Health Care

Price Target

Initiation

Analyst Ratings

Trading Ideas

General

Truist initiates coverage of Guardian Pharmacy, projecting a $22 price target due to strong growth in the $24.8 billion institutional pharmacy market.

Newly Listed Guardian Pharmacy Is Well Positioned In Highly Fragmented Market, Analyst Initiates With Buy Rating

Stock market analysts

SRPT

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Guardian Pharmacy Services, Inc. Class A Common Stock

Guardian Pharmacy Services Inc

Barclays analyst Alex Scott maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Underweight and raises the price target from $278 to $302.

Barclays Maintains Underweight on Willis Towers Watson, Raises Price Target to $302

On Thursday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) raised its mid-term sales guidance, increasing its compound annual growth rate (CAGR) target to 6% from 5% for 2023-2028.
The upgrade reflects performance from current growth drivers and anticipated launches, many of which are expected to retain U.S. exclusivity into the 2030s.
The <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-upgrades-mid-term-guidance-and-highlights-deep-pipeline-core-therapeutic-areas-drive-long-term-growth" rel="noreferrer noopener">updated</a> forecast, announced ahead of the company's Meet Novartis Management event in London, underscores its confidence in sustained momentum.
Novartis has outlined its projections for 2024-2029, maintaining a 5% CAGR target with 2024 as the base year.
The company remains on track to achieve a core operating income margin of over 40% by 2027, supported by continued sales growth and productivity enhancements.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni" rel="noreferrer noopener">Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights</a>
The company said the business is gaining strong momentum, with eight marketed brands expected to generate $3 billion to $8 billion at peak sales.
CEO Vas Narasimhan noted increased peak sales estimates for flagship drugs, including Cosentyx, Kisqali, Kesimpta, Pluvicto, and Leqvio, alongside 15 pivotal submission-enabling readouts in the pipeline.
He highlighted the company's long-term strategy, identifying more than 30 promising pipeline assets poised to rejuvenate its portfolio and sustain mid-single-digit growth beyond 2029.
Over the past two years, Novartis has executed more than 30 deals targeting exploratory and preclinical stages. Recent acquisitions, such as Kate Therapeutics and a collaboration with Ratio Therapeutics, bolster its radioligand and gene therapy pipelines, expanding opportunities in neuromuscular and radiotherapeutic advancements.
In October, Novartis reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41598312/novartis-q3-earnings-beats-expectations-on-strong-sales-from-key-drugs-lifts-2024-outlook" rel="noreferrer noopener">points to growth</a>.
The company said, "All key growth drivers contributed to the momentum. We achieved important indications expansions for&nbsp;Kisqali&nbsp;in early breast cancer and&nbsp;Fabhalta&nbsp;in IgA nephropathy&#8230;"
Novartis has <a target="_blank" href="https://www.novartis.com/stories/addressing-unmet-needs-inherited-neuromuscular-diseases" rel="noreferrer noopener">acquired</a> Kate Therapeutics to enhance and strengthen its portfolio of gene therapies.
Kate Therapeutics is a San Diego-based, preclinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined neuromuscular diseases.&nbsp;
The transaction value is up to $1.1 billion, comprising an upfront payment and potential additional milestone payments.
Kate Therapeutics' primary programs include preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1.
Price Action: NVS stock is up 0.24% at $103.34 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42098042/carlyle-sells-quidelortho-shares-analyst-sees-overhang-lifted" target="_blank" rel="noreferrer noopener">Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted</a></li>
</ul>
Photo by Taljat David via Shutterstock

Biotech

Large Cap

Guidance

Eurozone

Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline

BMO Capital analyst Keith Bachman maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Outperform and raises the price target from $390 to $425.

PANW

BMO Capital Maintains Outperform on Palo Alto Networks, Raises Price Target to $425

Warren Buffett is a master of making money – and Coca-Cola is <a href="https://www.benzinga.com/startups/24/11/42011977/99-billion-bet-warren-buffett-invests-heavily-in-2-stocks-expected-to-jump-19-and-20-wall-street-analysts-predict">one of his biggest cash cows</a>. In 2024, Berkshire Hathaway, Buffett's investment behemoth, is set to rake in $776 million in Coca-Cola dividends alone.&nbsp;
Don't Miss:
<ul>
<li>This rooftop wind turbine is taking on a market projected to reach over $900 billion by 2032 —<a href="https://www.benzinga.com/money/halcium"> With already over 40,000 users signing up to purchase, here's a chance to be an early investor today!</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai-2"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before it closes tonight.</a></li>
</ul>
That's right: $776 million for holding 400 million shares. According to Moneywise, this massive payout comes from Coca-Cola upping its quarterly dividend to 48.5 cents per share. If you're doing the math, that's $0.485 x 4 x 400,000,000. It&#8217;s not a bad haul for simply sitting on a mountain of Coke stock.
Buffett's love for Coca-Cola isn't just financial – it's personal. The 94-year-old billionaire famously drinks five cans daily and gets roughly 25% of his daily calories from the fizzy stuff. In a 2015 Fortune interview, he admitted, "If I eat 2,700 calories daily, a quarter of that is Coca-Cola. I drink at least five 12-ounce servings. I do it every day."&nbsp;
However, despite being Coca-Cola's largest shareholder and perhaps its most dedicated fan, Buffett doesn't get his favorite beverage for free. As revealed in the 2017 HBO documentary Becoming Warren Buffett, his wife Astrid even goes out of her way to buy the soda on sale. According to Buffett's daughter, Susie, her dad doesn't have room to stockpile the soda, but her mother bought it in bulk for the best price when she was alive.&nbsp;
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
Susie also revealed her famously frugal father's second wife, Astrid, also likes to get a deal. "Astrid is more likely to try to find out where it's on sale and buy it on sale."&nbsp;
While it may seem like Buffett has been a Coca-Cola lover forever, he once only drank its rival. <a href="https://www.benzinga.com/personal-finance/24/10/41198368/warren-buffetts-son-who-famously-cashed-in-his-90-000-inheritance-at-19-spends-millions-in-buffe">His son</a>, Howard, even called him "Pepsi Warren." He reportedly drank Pepsi for nearly 50 years before switching brands in the 1980s.&nbsp;
Buffett's switch from Pepsi to Coca-Cola reportedly had to do with his neighbor, Don Keough, a coffee salesperson in Omaha in the 1960s. According to Glen Arnold in The Deals of Warren Buffett Volume 2, Buffett once knocked on Keough's door with a pitch: "If you give me $10,000, I might be able to do something with it." Keough wasn't sold. "I didn't have it, but I could've borrowed it from my father. But can you imagine giving $10,000 to a guy who doesn't get up and go to work in the morning?" he later said. Keough passed on the offer, which Arnold estimated could've grown to $93 million by 2018.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Years later, Keough climbed the corporate ladder at Coca-Cola, becoming its president and COO in the 1980s. Keough seized the moment when he read in a magazine that Buffett was hooked on Pepsi Cherry. He sent his old neighbor some Cherry Coke samples, calling it the "<a href="https://www.benzinga.com/general/24/02/37240748/warren-buffett-drinks-5-cans-of-coke-per-day-at-93-years-old-but-he-was-a-dedicated-pepsi-drinker-fo">nectar of the gods</a>." Buffett was hooked. In 1986, he even told Berkshire Hathaway shareholders that Cherry Coke was now the official drink of their annual meeting, cementing his switch – and his eventual investment – in Coca-Cola.
Buffett&#8217;s 400 million shares of Coca-Cola stock represent a massive portion of his investment portfolio, worth over $25 billion at current market prices. But this investment is more than just numbers – it's a perfect example of Buffett's <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">long-term approach to investing</a> and his connection to the brand, even if he does have to buy it on sale.&nbsp;
Read Next:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai-2">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in less than 24 hours</a>!</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
</ul>

Warren Buffett Is Set To Collect $776 Million In Coca-Cola Dividends – But Daughter Says His Wife Buys Him The Soda 'On Sale'

BMO Capital analyst Kelly Bania maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Market Perform and lowers the price target from $160 to $120.

BMO Capital Maintains Market Perform on Target, Lowers Price Target to $120

ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) disclosed on Wednesday that it signed the appropriate partner&nbsp;agreements for its supply chain to sell its ZenaDrone 1000 AI drone<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42109018/zenatech-signs-blue-uas-and-ndaa-compliant-supply-chain-partners-to-sell-to-us-defense-branches-an" rel="noreferrer noopener"> solutions to US defense branches and NATO forces</a>.
The company recently participated in a Taiwan Trade Mission organized by the Arizona Commerce Authority (ACA) that directly resulted in these partnerships.
ZenaTech confirmed that all electrical components and the supply chain for its ZenaDrone 1000 will comply with the U.S. National Defense Authorization Act (NDAA) standards.
The company previously completed successful paid trials with the U.S. Air Force and U.S. Naval Research, utilizing its drones for transporting critical cargo, such as blood, in field operations.
NDAA compliance involves adhering to the provisions of the National Defense Authorization Act, which sets the annual budget and expenditure guidelines for the U.S. Department of Defense (DoD) while addressing cybersecurity concerns.
To be NDAA compliant, products must not be sourced from a list of prohibited Chinese manufacturers, covering components such as chipsets, cameras, and displays.
The Blue UAS program is a government-approved supplier list for drone companies seeking to do business with the U.S. DoD. Suppliers must meet strict NDAA cybersecurity and supply chain sourcing standards.
The Green UAS program offers a similar process but with a more streamlined approach and without restrictions on the country of origin for manufacturing.
CEO Shaun Passley, said, &#8220;Our strategic relationship with the Arizona Commerce Authority has resulted in these important NDAA-compliant partners needed in order to qualify for the Blue UAS list. The next step is to complete the Green UAS list process, then we will be ready for the Blue UAS certification to be able to execute our plans to do more business with military organizations in the US, NATO and beyond.&#8221;
Price Action: ZENA shares are up 0.33% at $1.525 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42111372" target="_blank" rel="noreferrer noopener">Dan Ives Predicts Nvidia&#8217;s Blackwell Chips Are Heading For &#8216;Massive Demand Trajectory&#8217; As Jensen Huang Says &#8216;LeBron Of Chip Releases&#8217; To Surpass Hopper GPU Shipments</a></li>
</ul>

Contracts

Small Cap

ZENA

ZenaTech Secures Key Supply Chain Deals For ZenaDrone 1000 AI Drone Solutions: Details

RBC Capital analyst Matthew Hedberg reiterates N-able (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>) with a Outperform and maintains $15 price target.

Reiteration

NABL

RBC Capital Reiterates Outperform on N-able, Maintains $15 Price Target

Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) co-founder Charles Hoskinson on Thursday named Coinbase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) CEO Brian Armstrong for a potential crypto position at the White House, citing his unique position to bridge the gap between the digital asset <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42091821/could-donald-trumps-potential-treasury-secretary-be-out-of-his-depth-on-crypto-policy-polymarket-traders-just-cant-decide-on-a-favorite">industry and federal regulators.</a>
What Happened: Hoskinson <a href="https://x.com/IOHK_Charles/status/1859312190219862175">emphasized</a> the importance of the role being filled by someone &#8220;neutral&#8221; with a deep understanding of blockchain technology and the challenges posed by existing U.S. regulations.
"There is only one candidate that I think stands out in our industry for this role, and that's Brian Armstrong," Hoskinson wrote. 
He cited Armstrong's leadership at Coinbase, a company that has navigated significant regulatory hurdles, as a testament to his ability to unify the industry and drive meaningful policy reform.
A crypto position, <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42098407/donald-trump-reportedly-eyeing-the-first-crypto-focused-role-in-the-white-house">reportedly</a> being considered by President-elect Donald Trump's transition team, would mark the first time a White House role is dedicated exclusively to <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40001426/trump-aims-to-make-us-crypto-capital-of-the-planet-well-get-it-done">cryptocurrency policy</a>.
The position is expected to act as a bridge between the White House, Congress, and federal regulatory agencies, aiming to create a cohesive and supportive regulatory framework for digital assets.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42090657/microstrategy-upsizes-convertible-notes-offering-to-2-6-billion-for-bitcoin-purchases">MicroStrategy Upsizes Convertible Notes Offering To $2.6 Billion For Bitcoin Purchases</a>
Hoskinson's nomination of Armstrong comes as the blockchain industry anticipates major shifts under Trump's administration, which has promised a more <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">crypto-friendly approach</a>.
Trump's campaign pledges included <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41680397/who-will-replace-gary-gensler-the-top-candidates-for-sec-chair-after-the-election">firing SEC Chair Gary Gensler</a>, scaling back regulatory oversight, and creating a presidential advisory council on cryptocurrency.
Hoskinson expressed his belief that Armstrong's experience would enable him to build a "broad tent coalition" to unite the fragmented crypto industry. 
He also announced his own efforts to support the policy framework, revealing plans to meet lawmakers in Washington, D.C., and launch an initiative called Operation Baseline. 
This project will survey the cryptocurrency industry to identify inefficiencies and propose actionable solutions for policymakers.
"The time has come to get this done so that we all can get back to work changing the world," Hoskinson said.
Armstrong, who recently endorsed Trump's newly announced Department of Government Efficiency, is no <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42084945/coinbase-ceo-brian-armstrong-backs-doge-initiative-how-blockchain-could-transform-government-efficiency">stranger to public policy debates. </a>
Armstrong described DOGE as a "once-in-a-lifetime opportunity" to streamline government operations, reduce waste, and enhance economic freedom. 
His vision aligns with blockchain's potential to improve transparency, reduce fraud, and simplify complex bureaucratic processes.
The creation of a crypto role could provide Armstrong with the platform to advocate for initiatives such as blockchain-driven transparency in government and Armstrong's own fiscal policy proposals, including a constitutional amendment to cap government spending.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42086650/robinhood-positioned-as-top-crypto-deregulation-trade-says-bernstein">Robinhood Positioned As Top &#8216;Crypto Deregulation&#8217; Trade, Says Bernstein</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$DOGE

COIN

Coinbase CEO Brian Armstrong 'Stands Out' As Candidate For Donald Trump's Reported 'Crypto Czar' Position, Cardano Co-Founder Says

Barclays analyst Seth Sigman maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Underweight and raises the price target from $116 to $123.

Barclays Maintains Underweight on Williams-Sonoma, Raises Price Target to $123

Oppenheimer analyst Leland Gershell reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Outperform and raises the price target from $646 to $675.

ARGX

Oppenheimer Reiterates Outperform on argenx, Raises Price Target to $675

RBC Capital analyst Matthew Hedberg reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Outperform and maintains $450 price target.

RBC Capital Reiterates Outperform on Palo Alto Networks, Maintains $450 Price Target

Offering Advertisers Enhanced Reach And Targeting Across Xumo Properties With PubMatic's Supply Path Optimization Capabilities

PUBM

Xumo Partners With PubMatic To Expand Programmatic Advertising

Oppenheimer analyst Ittai Kidron maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and maintains $180 price target.

SNOW

Oppenheimer Maintains Outperform on Snowflake, Maintains $180 Price Target

<a href="https://www.capitoltrades.com/issuers/435690" title="https://www.capitoltrades.com/issuers/435690">https://www.capitoltrades.com/issuers/435690</a>

Politics

VSAT

Watcing ViaSat; Traders Circulate Representative Debbie Wasserman Schultz Has Bought Stock In The Company

Financial giants have made a conspicuous bullish move on Super Micro Computer. Our analysis of options history for Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) revealed 13 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $2,286,540, and 9 were calls, valued at $866,659.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $24.0 and $75.0 for Super Micro Computer, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Super Micro Computer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Super Micro Computer's substantial trades, within a strike price spectrum from $24.0 to $75.0 over the preceding 30 days.
<h3>Super Micro Computer Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732201572_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.3</td>
<td>$48.1</td>
<td>$48.8</td>
<td>$75.00</td>
<td>$1.4M</td>
<td>551</td>
<td>298</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$29.95</td>
<td>$28.6</td>
<td>$29.25</td>
<td>$53.00</td>
<td>$731.2K</td>
<td>1.4K</td>
<td>250</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.45</td>
<td>$3.3</td>
<td>$3.45</td>
<td>$30.00</td>
<td>$312.3K</td>
<td>12.8K</td>
<td>455</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.5</td>
<td>$6.4</td>
<td>$6.4</td>
<td>$24.00</td>
<td>$205.4K</td>
<td>2.6K</td>
<td>335</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.85</td>
<td>$5.75</td>
<td>$5.75</td>
<td>$35.00</td>
<td>$115.0K</td>
<td>5.2K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Super Micro Computer</h3>
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data center, Big Data, high-performance computing, and "Internet of Things" embedded markets. Its solutions include server, storage, blade and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
In light of the recent options history for Super Micro Computer, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Super Micro Computer's Current Market Status</h3>
<ul>
<li>With a volume of 21,385,693, the price of SMCI is up 7.98% at $27.86. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Super Micro Computer options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

SMCI

Smart Money Is Betting Big In SMCI Options

Investors with a lot of money to spend have taken a bullish stance on Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BAC, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Bank of America.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 37%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $27,620, and 7, calls, for a total amount of $677,470.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $48.0 for Bank of America, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Bank of America stands at 10933.33, with a total volume reaching 15,601.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Bank of America, situated within the strike price corridor from $45.0 to $48.0, throughout the last 30 days.
<h3>Bank of America Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732201567_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.56</td>
<td>$0.54</td>
<td>$0.55</td>
<td>$48.00</td>
<td>$183.2K</td>
<td>12.5K</td>
<td>4.8K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.96</td>
<td>$0.95</td>
<td>$0.95</td>
<td>$47.00</td>
<td>$142.5K</td>
<td>26.4K</td>
<td>3.0K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$0.96</td>
<td>$0.95</td>
<td>$0.95</td>
<td>$47.00</td>
<td>$95.0K</td>
<td>26.4K</td>
<td>5.0K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.66</td>
<td>$1.63</td>
<td>$1.65</td>
<td>$47.00</td>
<td>$82.5K</td>
<td>23.2K</td>
<td>506</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.51</td>
<td>$0.5</td>
<td>$0.51</td>
<td>$48.00</td>
<td>$77.2K</td>
<td>12.5K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About Bank of America</h3>
Bank of America is one of the largest financial institutions in the United States, with more than $3.0 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.
In light of the recent options history for Bank of America, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Bank of America's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,855,697, the price of BAC is up by 1.17%, reaching $46.6.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
<h3>What The Experts Say On Bank of America</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $55.333333333333336.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Bank of America with a target price of $56. 
&#x2A; An analyst from Citigroup upgraded its action to Buy with a price target of $54. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Bank of America, maintaining a target price of $56. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bank of America with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Bank of America Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MSTR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 348 extraordinary options activities for MicroStrategy. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 30% leaning bullish and 41% bearish. Among these notable options, 68 are puts, totaling $8,017,465, and 280 are calls, amounting to $41,504,526.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $69.0 to $990.0 for MicroStrategy over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for MicroStrategy's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of MicroStrategy's whale activity within a strike price range from $69.0 to $990.0 in the last 30 days. 
<h3>MicroStrategy Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732201562_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$261.0</td>
<td>$237.45</td>
<td>$253.92</td>
<td>$760.00</td>
<td>$1.3M</td>
<td>980</td>
<td align="right">257</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$215.15</td>
<td>$198.5</td>
<td>$202.92</td>
<td>$890.00</td>
<td>$1.1M</td>
<td>1.1K</td>
<td align="right">270</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$43.8</td>
<td>$41.5</td>
<td>$43.8</td>
<td>$472.50</td>
<td>$701.6K</td>
<td>322</td>
<td align="right">210</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$44.65</td>
<td>$39.85</td>
<td>$39.65</td>
<td>$475.00</td>
<td>$669.9K</td>
<td>567</td>
<td align="right">336</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$123.0</td>
<td>$113.2</td>
<td>$116.0</td>
<td>$600.00</td>
<td>$425.4K</td>
<td>1.1K</td>
<td align="right">263</td>
</tr>
</tbody>
</table>

<h3>About MicroStrategy</h3>
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; MicroStrategy Server, which provides analytical processing and job management. The company's reportable operating segment is engaged in the design, development, marketing, and sales of its software platform through licensing arrangements and cloud-based subscriptions and related services.
After a thorough review of the options trading surrounding MicroStrategy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of MicroStrategy</h3>
<ul>
<li>Trading volume stands at 15,686,064, with MSTR's price up by 11.48%, positioned at $528.22.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 75 days.</li>
</ul>
<h3>What Analysts Are Saying About MicroStrategy</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $349.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for MicroStrategy, targeting a price of $300. 
&#x2A; An analyst from TD Cowen persists with their Buy rating on MicroStrategy, maintaining a target price of $300. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for MicroStrategy, targeting a price of $275. 
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Buy rating for MicroStrategy, targeting a price of $300. 
&#x2A; Maintaining their stance, an analyst from BTIG continues to hold a Buy rating for MicroStrategy, targeting a price of $570. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MicroStrategy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

MSTR

Check Out What Whales Are Doing With MSTR

Oppenheimer analyst Brian Schwartz reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Outperform and raises the price target from $330 to $385.

Oppenheimer Reiterates Outperform on Salesforce, Raises Price Target to $385

Quantum-Si Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares tanked over <a href="https://www.benzinga.com/general/health-care/24/11/42091430/nvidia-partners-with-quantum-si-to-advance-single-molecule-analysis">12.8% Thursday morning</a>.
The company plans to introduce Platinum Pro, an advanced version of its Platinum platform, in the first half of 2025. Platinum Pro will feature a streamlined workflow, reducing hands-on time and speeding up processing.
It will support both local and cloud-based data analysis, and introduce a &#8216;Pro Mode&#8217; for custom application development, offering a valuable tool for biopharmaceutical clients.
On the other hand, Quantum-Si will launch Proteus in the second half of 2026.
Proteus is expected to offer advanced capabilities, including ultrasensitive detection of proteoforms, unbiased analysis of complex samples, and a new rapid sequencing chemistry that reduces run time to 90 minutes or less.
The company expects Proteus to serve as the foundational platform for scaling sequencing output, progressing from tens of millions of reads per sample at launch to billions over time.
CEO Jeff Hawkins expects Proteus to &#8220;open broad new markets for diverse applications in protein analysis, driving increased revenue growth that will create significant value for our shareholders.&#8221;
&#8221;With these technology advancements and partnerships in place, we believe we will be able to further extend our leadership position in next-generation protein sequencing while also extending into other areas of proteomics more generally.&#8221;
To accelerate the development of Proteus and mitigate risks in the hardware platform delivery, Quantum-Si recently announced new partnerships and collaborations.
Yesterday, Quantum-Si announced a collaboration with Nvidia to develop its new proteomics platform.
Also, the company entered into a distribution agreement with Avantor, as per which, Avantor will distribute Quantum-Si&#8217;s Next-Generation Protein Sequencing (NGPS) portfolio in the U.S. and Canada, offering researchers across various market segments easier access t<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42085520/avantor-to-distribute-quantum-sis-next-generation-protein-sequencing-technology" rel="noreferrer noopener">o these innovative proteomics solutions</a>.
Price Action: Quantum-Si shares are down 12.88% at last check Thursday, trading around $1.21 a share. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42107830" target="_blank" rel="noreferrer noopener">Uber Could Pick Up $10M Stake In Chinese Autonomous Driving Firm Pony AI&#8217;s US IPO: Report</a></li>
</ul>
Image via Quantum-Si

Quantum-Si Shares Slip After Next-Gen Proteomics Platforms Are Unveiled

Barclays analyst Saket Kalia maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Overweight and raises the price target from $200 to $220.

Barclays Maintains Overweight on Zscaler, Raises Price Target to $220

IPO Roundup: FrontView REIT, StandardAero and more

Guardian Pharmacy Services: Questions After A Successful IPO

ClearBridge Small Cap Strategy Q3 2024 Commentary

Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies – Springview, Oriental Rise, PTL, Samfine C...

Opening Day: Self-driving startup Pony.ai files for U.S. IPO

Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group -- saw their stocks open for trading.

Self-Driving Startup Pony.ai Files For U.S. IPO

Truist initiated coverage of Guardian Pharmacy (GRDN) Services with a Buy rating and $22 price target The provider of long-term care facility, or L...

Guardian Pharmacy initiated with a Buy at Truist

Reports Q3 revenue $314.4M, consensus $303.2M. "After successfully completing our IPO in September, we are happy to report that our first quarter a...

Guardian Pharmacy reports Q3 adjusted EBITDA $23.0M, up 20% y/y

Guardian Pharmacy Services reports Q3 results

Guardian Pharmacy Services, Inc. Class A ( ($GRDN) ) has released its Q3 earnings. Here is a breakdown of the information Guardian Pharmacy Service...

Guardian Pharmacy Services Reports Strong Revenue Growth

Truist raised the firm's price target on Guardian Pharmacy (GRDN) to $24 from $22 and keeps a Buy rating on the shares. The firm is adjusting its m...

Guardian Pharmacy price target raised to $24 from $22 at Truist

ACTHF

AEIS

APOS

APUS

AVNT

BIGC

BIOA

CFCV

CHARU

CORT

CSTM

CTNM

CTRI

CUPR

EVRI

FBGL

HAIN

HELE

HUHU

INDI

INFR

INSM

LGCY

LNTH

LRGE

LUMN

MAMO

MSFT

MTDR

MYPS

MYPSW

ORIS

PCVX

PTLE

SARO

SEAT

SEATW

SFHG

SLGN

SNYRD

SPHL

SUNH

TARS

TGLS

TLIH

TMGX

VRNA

WSFS

XPRO

YLDE

ZBAO

Press Releases

Guardian Pharmacy Services, Inc. Announces Pricing of Upsized Initial Public Offering

Guardian Pharmacy Services, Inc. to Report Third Quarter 2024 Financial Results and Host Conference Call

Comments

Guardian Pharmacy Service

Guardian Pharmacy Service (GRDN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga